TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.

Xi Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.